Immunic to Participate in Scientific and Industry Conference

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

Related Keywords

Germany , Netherlands , Cleveland , Ohio , United States , Italy , Vienna , Wien , Austria , Russia , Amsterdam , Noord Holland , Ukraine , Franziska Buri , Edna Kaplan , Heinz Wiendl , Konrad Rejdak , Thomas Polasek , Inge Kehler , Andreas Muehler , Hella Kohlhof , Paula Schwartz , Plamen Stoyanov Bozhinov , Johann Sellner , Evelyn Peelen , Iryna Skrypchenko , Nataliya Tomakh , Christian Wolf , Daniel Vitt , Viktoriia Gryb , Juliano Fonseca , Jessica Breu , Jelena Mihajlovic , Robertj Fox , Mellen Center , Free Communications , Rx Communications Group , Prnewswire Immunic Inc , Nasdaq , Exchange Commission , International Celiac Disease Symposium , Neurologic Institute , Research In Multiple Sclerosis , Immunic Inc , European Committee For Treatment , United European Gastroenterology , Medical Director , First In Human Trial , Orally Available Tight Junction Regulator , Amelie Schreieck , European Committee , Multiple Sclerosis , Staff Neurologist , Cleveland Clinic , Neuroprotective Efficacy Variables , Vidofludimus Calcium , Placebo Controlled Phase , Relapsing Remitting Multiple , Nicola De Stefano , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Immunic , Nc ,